Skip to main content

Glumetza FDA Approval History

FDA Approved: Yes (First approved June 3, 2005)
Brand name: Glumetza
Generic name: metformin extended release
Dosage form: Tablets
Company: Biovail Corporation/Depomed, Inc.
Treatment for: Diabetes, Type 2

Glumetza (metformin extended-release) is a once-daily oral antihyperglycemic formulation indicated for the treatment of type 2 diabetes.

Development timeline for Glumetza

Jan  2, 2008Approval Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
Jun  3, 2005Approval FDA Approves Glumetza for Type 2 Diabetes
Apr 13, 2005Depomed, Biovail Update Status of Glumetza NDA
Mar  1, 2005Biovail, Depomed Receive Approvable Letter from FDA for Extended-Release Glumetza for Type II Diabetes
Jun 24, 2004Biovail, Depomed Announce Glumetza NDA Accepted by FDA
Apr 28, 2004Biovail and Depomed Submit NDA for Glumetza; Submission Includes 500mg and 1000mg dosages; Biovail/Depomed Expand Royalty Agreement to Include 1000mg dose

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.